Loading data for ARTL — first visit, this takes a few seconds.
Artelo Biosciences Inc. (ARTL)
NasdaqCM: ARTL
· Real-Time Price · USD
0.71
-0.02 (-2.74%)
At close: Aug 19, 2026, 6:43 PM
Artelo Biosciences Inc. (ARTL) Stock Price, Analysis & Data
-2.74% (1D)
No data available
| Bid | 0.52 |
| Market Cap | 3.31M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -13.46M |
| Beta | -0.07 |
| EPS (ttm) | -11.23 |
| PE Ratio (ttm) | n/a |
| Forward PE | -0.82 |
| P/B (ttm) | -0.38 |
| P/S (ttm) | n/a |
| Earnings Date | n/a |
| Ask | 0.92 |
| Volume | 161,408 |
| Avg. Volume (20D) | 1,108,640 |
| Open | 0.72 |
| Previous Close | 0.73 |
| Day's Range | 0.71 - 0.75 |
| 52-Week Range | 0.69 - 30.00 |
| Analyst | n/a |
| Price Target | n/a |
| Dividends | n/a |
| Ex-Dividend Date | n/a |
About ARTL
Artelo Biosciences, Inc., a clinical stage biopharmaceutical company, develops and commercializes therapeutics that target lipid-signaling pathways in the United States. The company's product candidate pipeline includes ART27.13, a synthetic dual cannabinoid G protein-coupled receptor agonist, which is in Phase 1b/2a clinical trial for the treatment of cancer-related anorexia; and ART12.11, a cocrystal composition of cannabidiol and tetramethylpy...
Industry Biotechnology
Sector Healthcare
IPO Date Jun 21, 2019
Employees 7
Stock Exchange NasdaqCM
Ticker Symbol ARTL
Website https://artelobio.com
Financial Performance
In 2025, Artelo Biosciences's revenue was 0, an increase of undefined% compared to the previous year's 0. Earnings were -12.88M, an increase of 31.07%.
Financial StatementsEarnings Surprise
Artelo Biosciences has released their quarterly earnings on Feb 24, 2026:
